-
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:19-cv-00203
- N.D.W. Va.
- Judge: John Preston Bailey
- Filed: 11/04/2019
- Closed: 03/08/2023
- Latest Docket Entry: 03/08/2023
- PACER
2
Plaintiffs
2
Defendants
2
Accused
Products
5
Patents-in-Suit
1,610
Days in
Litigation
-
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:19-cv-00203
- N.D.W. Va.
- Judge: John Preston Bailey
- Filed: 11/04/2019
- Closed: 03/08/2023
- Latest Docket Entry: 03/08/2023
- PACER
Transferred From
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Valid
Entry 182 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 9 |
The method of claim 4, wherein the concentration of budesonide is 2 mg/ml.
|
Enforceable and Valid
Entry 183 |
| 10 |
The method of claim 4, wherein the concentration of budesonide is 4 mg/ml.
|
Enforceable and Valid
Entry 183 |
| 13 |
A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 2
view more
|
Enforceable and Valid
Entry 183 |
| 14 |
A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 4
view more
|
Enforceable and Valid
Entry 183 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 12 |
The inhaler of claim 10, wherein an actuation of the inhaler delivers 80 μg budesonide.
|
Enforceable and Valid
Entry 183 |
| 13 |
The inhaler of claim 10, wherein an actuation of the inhaler delivers 160 μg budesonide.
|
Enforceable and Valid
Entry 183 |
| 18 |
The method of claim 16, wherein an actuation of the inhaler delivers 80 μg budesonide.
|
Enforceable and Valid
Entry 183 |
| 19 |
The method of claim 16, wherein an actuation of the inhaler delivers 160 μg budesonide.
|
Enforceable and Valid
Entry 183 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 10 |
The pharmaceutical suspension composition of claim 9, wherein the PEG-1000 is present at a concentration of 0.3% w/w.
|
Enforceable and Valid
Entry 183 |
| 19 |
A method of treating a respiratory disorder, the method comprising administering the pharmaceutical suspension composition of claim 10 to a patient identified as in need of treatment with the composition.
|
Enforceable and Valid
Entry 183 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The composition according toclaim 1 wherein the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w.
|
Invalid
Entry 208 Entry 207 |
| 3 |
The pharmaceutical composition according toclaim 1 in which the PVP is PVP K25.
|
Invalid
Entry 208 Entry 207 |
| All Claims |
NA
|
Valid
Entry 182 |
-
Infringement
Kindeva Drug Delivery L.P.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 7,759,328 B2 |
9, 10, 13, 14
|
Infringement
Entry 183
|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 8,143,239 B2 |
12, 13, 18, 19
|
Infringement
Entry 183
|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 8,575,137 B2 |
10, 19
|
Infringement
Entry 183
|
Mylan Pharmaceuticals Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 7,759,328 B2 |
9, 10, 13, 14
|
Infringement
Entry 183
|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 8,143,239 B2 |
12, 13, 18, 19
|
Infringement
Entry 183
|
| 160 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol80 mcg/4.5 mcg Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol | US 8,575,137 B2 |
10, 19
|
Infringement
Entry 183
|